Profusa, Inc. (NASDAQ:PFSA) Short Interest Down 57.2% in June

Profusa, Inc. (NASDAQ:PFSA) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 123,461 shares, a decline of 57.2% from the May 31st total of 288,318 shares. Approximately 2.7% of the company’s shares are sold short. Based on an average trading volume of 412,104 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PFSA. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Profusa Price Performance

Shares of Profusa stock traded up $0.00 on Tuesday, hitting $0.12. 2,319,496 shares of the company’s stock traded hands, compared to its average volume of 3,846,370. Profusa has a one year low of $0.10 and a one year high of $180.00. The company has a fifty day moving average of $0.38 and a two-hundred day moving average of $2.81. The company has a market capitalization of $542,890.00, a price-to-earnings ratio of -0.00 and a beta of 0.35.

Profusa (NASDAQ:PFSA) last issued its earnings results on Friday, May 15th. The company reported ($2.05) earnings per share for the quarter.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.